Caenorhabditis elegans as a Model to Dissect Pharmacokinetic and Pharmacodynamic Relationships of Gabapentinoids

Gabapentin (GBP) and pregabalin (PGB) are commonly used gabapentinoid medications. In a recent study, researchers utilized the tiny roundworm C. elegans to examine how these drugs affect pain perception. The scientists employed thermal nociception assays, which measure how quickly an organism withdraws from a hot stimulus, to compare the drugs' effects.

Crucially, neither compound influenced the worms' normal movement patterns or preferred directions of movement, suggesting their impact was specific to pain perception. Both GBP and PGB demonstrated a two-part, V-shaped response to increased drug exposure over time. Initially, the drugs suppressed the worms' sensitivity to heat before eventually allowing some sensitivity to return.

This rebound effect was more pronounced for PGB than GBP. Laboratory measurements confirmed that the drugs absorbed into the worms' bodies at increasing concentrations, but at 500 micrograms per milliliter, levels remained high even after behavioral effects faded. This indicates the behavioral recovery was driven by the drugs' active regulation, not just their elimination from the body, aligning with earlier findings on gene and protein changes.

The study's exposure-response patterns were relatively flat, implying a threshold where the drugs became less responsive to higher doses. In terms of molecular mechanisms, modeling showed both drugs target a similar protein, the alpha-2-delta subunit, though subtle differences might affect how quickly they enter the worms. Overall, these results highlight C. elegans as a useful tool for understanding gabapentinoid pharmacokinetics (how the body handles the drugs) and pharmacodynamics (how the drugs affect the body).

Beyond theoretical insights, the findings support ongoing efforts to use C. elegans in animal research that adheres to the 3R principles of replacement, reduction, and refinement.